Esprit takes eight percent in pharma merger

Venture capital firm Esprit Capital Partners has acquired a Canadian drug company to merge with its existing portfolio business Kiadis Pharma.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this